Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Evidence not strong enough to support routine use of DCBs for STEMI

5 days ago

While drug-coated balloons (DCBs) perform largely comparably to drug-eluting stents (DESs), there is still insufficient evidence to recommend its routine use in patients with ST-elevation myocardial infarction (STEMI), reports a new meta-analysis.

The quantitative analysis included three studies, corresponding to 284 STEMI patients, of whom 138 received DCBs and the remaining 146 were given DESs. Two of the eligible studies were randomized controlled trials (RCT), while the last one was a post-hoc analysis of an RCT.

Target lesion revascularizations occurred more commonly in DCB-treated patients, but not significantly so. The resulting risk estimate was likewise nonsignificant (6.5 percent vs 2.7 percent; odds ratio [OR], 2.51, 95 percent confidence interval [CI], 0.76–8.25; p=0.13).

Similarly, acute thromboses (2.9 percent vs 0 percent; OR, 5.16, 95 percent CI, 0.59–44.97; p=0.14) and major adverse cardiac events (6.5 percent vs 3.4 percent; OR, 1.98, 95 percent CI, 0.69–5.74; p=0.21) were both only nominally elevated in DCB vs DES patients.

The same was also true for myocardial infarctions (1.4 percent vs 1.3 percent; OR, 0.97, 95 percent CI, 0.13–7.29; p=0.98) and all-cause mortality (0.7 percent vs 0 percent; OR, 3.76, 95 percent CI, 0.15–94.83; p=0.42).

On the other hand, type D or worse coronary dissections occurred in a significantly greater frequency in DCB patients (14.5 percent vs 0 percent; OR, 18.4, 95 percent CI, 3.48–93.61; p=0.0006). This contributed to bailout stenting with a bare-metal stent, which also occurred more frequently in DES patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.